Providers using REACH Health's enterprise telemedicine platform have a higher rate of administering a clot-dissolving drug in stroke patients than the national average.
Tissue Plasminogen Activator is a clot-dissolving drug that can treat many patients suffering from acute ischemic stroke, but tPA can only be administered within three hours of the onset of stroke symptoms. This can make tPA administration more difficult for smaller or remote hospitals who have to transfer patients to a stroke center.
The national average tPA administration rate is 10 percent, according to REACH Health, but providers using their REACH Access telehealth platform report an average tPA administration rate of approximately 35 percent.
"We believe that the advanced clinical workflow in REACH Access enhances remote collaboration and enables faster and more accurate clinical diagnoses," said Steve McGraw, president and CEO of REACH Health.
More articles on telemedicine:
4 key elements to a great telemedicine system
Physicians use telemedicine to prevent spread of flu
Lafayette General launches telemedicine initiative in local schools